Controversies in surgical management of advanced ovarian cancer;Kontroverser ved kirurgisk behandling av avansert ovarialcancer

Tidsskrift for den Norske Laegeforening

Volumn 120, Issue 7, 2000, Pages 824-830

  Tropé, Claes ^a   Paulsen, Torbjørn ^a   Baekelandt, Mark ^a   Makar, Amin ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; EVIDENCE BASED MEDICINE; FEMALE; GYNECOLOGIC SURGERY; HUMAN; LAPAROSCOPY; LYMPHADENECTOMY; MEDICAL ILLUSTRATION; METASTASIS; METHODOLOGY; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; REVIEW;

EVIDENCE-BASED MEDICINE; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; LAPAROSCOPY; LYMPH NODE EXCISION; MEDICAL ILLUSTRATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 0034628794     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Haybittle JL, Kingley-Pillers EM. Long term survival experience of female patients with genital cancer. Br J Cancer 1988; 57: 322-5.
2. Petterson F. Annual report on the results of treatment in gynecological cancer (suppl 22). Stockholm: Radiumhemmet, 1995.
3. Balvert-Locht HR, Coebergh JWW, Hop WCJ, Brolmann HA, Crommelin M, van Wijk DJ et al. Improved prognosis of ovarian cancer in the Netherlands during the period 1975-1985: a registry based study. Gynecol Oncol 1991; 42: 3-8.
4. Piver MS. Ovarian carcinoma: a decade of progress. Cancer 1994; 54: 2706-15.
5. Bjørge T, Engeland A, Sundfør K, Tropé C. Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstet Gynecol Scand 1998; 77: 777-81.
6. Tropé C, Makar A. Epidemiology, etiology, screening, prevention and diagnosis in female genital cancer. Curr Opin Oncol 1991; 3: 908-19.
7. Griffiths CT. Surgery at the time of diagnosis in ovarian cancer. London: Butterworth, 1986: 60-75.
8. DeVita VT. Principles of chemotherapy. I: Devita VT, Hellman S, Rosenberg SA, red. Cancer: principles and practice of oncology. 4. utg. Philadelphia, PA: Lippincott, 1993: 276-99.
9. Goldie JH, Coldman JA. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 60: 1727-33.
10. Rubin SC, Hoskins WJ. Primary surgery for ovarian carcinoma. I: Sciarra JJ, Droegemueller W, red. Gynecology and obstetrics. Philadelphia, PA: Lippincott, 1993: 1-11.
11. Hoskins WJ. Primary cytoreduction. I: Markman M, Hoskins WJ, red. Cancer of the ovary. New York, NY: Raven, 1993: 163-73.
12. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998; 25: 326-34.
13. Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991; 18: 213-21.
14. Munnell EW. The changing prognosis and treatment in cancer of the ovary: a report of 235 patients with primary ovarian carcinoma 1952-61. Am J Obstet Gynecol 1968; 100: 790-805.
15. Griffith CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Mongr 1975; 42: 101-4.
16. Bertelsen K. Tumor reduction surgery and long term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990; 38: 230-40.
17. Heintz APM, van Oosterom AT, Trimbo JB. The treatment of advanced ovarian carcinoma (I): clinical, variables associated with prognosis. Gynecol Oncol 1988; 30: 347-58.
18. Heintz APM. Surgery in advanced ovarian carcinoma: is there proof to show the benefit? Eur J Surg Oncol 1988; 14: 91-9.
19. Hoskins JW, McGuire WP, Brady BS, Homesley HD, Creasman WT, Borman M. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974-80.
20. Makar AP, Baekelandt M, Tropé CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology and grade in patients with suboptimal residual epithelial ovarian carcinoma. Gynecol Oncol 1995; 56: 175-80.
21. Fiorica JV, Hoffman MS, LaPolla JP, Roberts WS, Cavanagh D. The management of diaphragmatic lesions in ovarian carcinoma. Obstet Gynecol 1989; 74: 927-9.
22. Patsner B. Carbon dioxide laser vaporization of diaphragmatic metastases for cytoreduction of ovarian epithelial cancer. Obstet Gynecol 1990; 76: 724-7.
23. Barnes W, Johnsen J, Waggoner S, Barter J, Potkul R, Delgado G. Reverse hysterocolposigmoidectomy (RHCS) for resection of panpelvic tumors. Gynecol Oncol 1991; 42: 151-5.
24. Eisenkop SM, Nalick RH, Teng NNH. Modified posterior exenteration for ovarian cancer. Obstet Gynecol 1991; 78: 879-85.
25. Podratz K, Malkasian GD, Wieand H, Cha SS, Lee RA, Stanhope CR et al. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 1988; 29: 274-82.
26. Farias-Eisner R, Oliviera M, Teng F. The influence of tumor distribution number and size after optimal cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol 1992; 46: 267.
27. Hoskins WJ, Bundy BN, Thigpen JT, Omura OA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1992; 47: 159-66.
28. Brand E, Pearlman N. Electrosurgical debulking of ovarian cancer: a new technique using the argon beam coagulator. Gynecol Oncol 1990; 39: 115-8.
29. Eisenkop S, Nalick R, Teng N. Peritoneal implant elimination cytoreductive surgery for ovarian cancer. The impact on survival. Gynecol Oncol 1993; 51: 224-9.
30. Eisenkop SM, Friedman RL, Wang HE. Complete cytoreductive surgery is feasible and maximises survival in patients with advanced epithelial ovarian cancer: a prospective study. Gyneiol Oncol 1998; 69: 103-8.
31. Hacker NF, Berek JS, Lagasse LD, Nieberg UK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-20.
32. Hacker N. Surgical management of advanced cvarian cancer. I: Lawton F, Neijt JP, Swenerton KD, red. Epithelial cancer of the ovary. London: BMJ publishing group, 1995: 144-71.
33. Webb MJ. Cytoreduction in ovarian cancer: achiveability and results. Baillieres Clin Obstet Gynecol 1989; 3: 83-94.
34. Piver MS, Baker T. The potential for optimal (≤ 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center. A prospective study. Gynecol Oncol 1986; 24: 1-8.
35. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton H. Primary surgical therapy of ovarian cancer: how much and when? Gynecol Oncol 1991; 40: 195-200.
36. Goodman HM, Harlow BL, Sheets EE. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 1992; 46: 367-71.
37. Curtin JP, Malik R, Venkatrman ES. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997; 64: 9-112.
38. Liu PC, Benjamin I, Morgan MA. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997; 64: 4-8.
39. Munkarah AR, Hallum AV III, Morris M. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997; 64: 13-7.
40. Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol 1993; 49: 86-91.
41. Kærn J, Tropé CG, Kjørstad KE, Abeler VM, Pettersen EO. Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol Oncol 1990; 38: 452-7.
42. Swenerton KD, Hislop TG, Spinelli J, Le Riche JC, Yang N, Boyes DA. Ovarian carsinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65: 264-9.
43. Krag KJ, Canellos GP, Griffith CT. Predictive factors for long term survival in patients with advanced cancer. Gynecol Oncol 1989; 34: 88-93.
44. Marsoni S, Torri V, Valsecchi MG, Belloni C, Bollis G, Bonazzi C et al (Gruppo Interregionale Cooperativo di Oncologica Ginologica (GICOG). Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 1990; 62: 444-50.
45. Schray M, Martinez A, Cox R, Ballon S. Radiotherapy in epithelial ovarian cancer: analyis of prognostic factors based on long term experience. Obstet Gynecol 1983; 62: 373-82.
46. Creasman WT, Omura GA, Brady MF, Yordane E, Disaia PS, Beechams J et al. A randomized trial of Cyclophosphamide, Doxorubicin and Cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 1990; 39: 239-43.
47. Malkasian GD, Melton LJ, O'Brian PC, Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 1984; 149: 274-82.
48. Makar AP, Kristensen GB, Kærn J, Børmer OP, Abeler VM, Tropé CG et al. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analyses. Obstet Gynecol 1992; 79: 1002-10.
49. Makar AP, Kristensen GB, Kærn J, Børmer OP, Trope CG. Serum CA 125 level allows early identification of nonresponders during induction chemptherapy. Gynecol Oncol 1993; 49: 73-9.
50. Makar AP, Tropé CG. Gynecologic malignancy and surgery: from quantity to quality of life. Curr Opin Obstet Gynecol 1992; 4: 419-29.
51. Burghardt E, Pickel H, Lahousen M, Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986; 155: 315-9.
52. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991; 40: 103-6.
53. Burghardt E, Pickel H, Stettner H. Management of advanced ovarian cancer. Eur J Gynaecol Oncol 1984; 3: 155-9.
54. Burghardt E, Winter R. The effect of chemotherapy on lymph node metastases in ovarian cancer. Baillieres Clin Obstet Gynaecol 1989; 3: 167-71.
55. Lanza A, D'addato F, Valli M, Bussone R, Caldarola B, Re A et al. Pelvic and para-aortic lymph nodal positivity in the ovarian carcinoma: its prognostic significance. Eur J Gynaecol Oncol 1988; 9: 36-9.
56. Podratz KC, Malkasian GD, Wiend HS, Cha SS, Lee RA, Stanhope J et al. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 1988; 29: 274-82.
57. Wu PC, He Lang J, Li Huang R, Yi Qu Lian LJ. Lymph node metastasis and retroperitoneal lymphadenectomy in ovarian cancer. Baillieres Clin Obstet Gynaecol 1989; 3: 143-55.
58. Blyth JG, Wahl TP. Debulking surgery: does it increase the quality of survival? Gynecol Oncol 1982; 14: 396-408.
59. Hunter RW, Alexander NDE, Soutter WP. Management of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992; 166: 504-11.
60. Heintz AP, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse AD. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986; 67: 783-8.
61. Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 1992; 79: 168-72.
62. Di Re F, Fontanelli R, Raspagliesi F, Di Re E. Pelvic and para-aortic lymphadenectomy in cancer of the ovary. Baillieres Clin Obstet Gynaecol 1989; 3: 131-42.
63. Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GR. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994; 101: 142-6.
64. van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G et al. The effect of debulking surgery after indication chemotherapy on the prognoses in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study. N Engl J Med 1995; 332: 629-34.
65. Van Dam PA, Decloedt J, Tjalma W, Buytaert P, Becquart D, Vergote I. Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced? Eur J Gynaecol Oncol 1997; 18: 272-3.
66. Friedman JB, Weiss NS. Second thought about second-look laparotomy in advanced ovarian cancer. N Engl J Med 1990; 322: 1079-82.
67. Cain JM, Saigo PE, Pierce VK, Clark DG, Jones WB, Smith D et al. A review of second-look laparotomy for ovarian cancer. Gynecol Oncol 1986; 23: 14-25.
68. Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin JM, Shingleton HM. Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol 1992; 44: 3-9.
69. Lund B, Williamson P. Prognostoc factors for outcome of and survival after second look laparotomy in patients with advanced ovarian carcinoma. Obstet Gynecol 1990; 76: 617-22.
70. Podczaski E, Manetta A, Kaminski P, Ricelli A, Larson J, De Geest K et al. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. Gynecol Oncol 1990; 36: 43-7.
71. Bertelsen K, Hansen KK, Pedersen PH, Larsen G, Nyland M, Jacobsen M et al. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer. Br J Obstet Gynecol 1988; 95: 1231-6.
72. Makar AP, Kristensen GB, Børmer OP, Tropé CG. CA 125 measured before second-look laparotmomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer. Gynecol Oncol 1992; 45: 323-8.
73. Berek JS, Tropé CG, Vergote I. Surgery during chemotherapy and or relapse of ovarian cancer. Ann Oncol 1999; 10: 53-7.
74. Hoskins WJ, Rubin SC, Dulaney E. Influence of secondary cytoreduction at the time of second-look laparotomy on survival of patients with ovarian cancer. Gynecol Oncol 1989; 34: 365-71.
75. Schwartz PE, Smith JP. Second-look operations in ovarian cancer. Am J Obstet Gynecol 1980; 138: 1124-30.
76. Raju KS, Mckinna JA, Barker GH. Second-look operations in the planned management of ovarian carcinoma. Am J Obstet Gynecol 1982; 144: 650-4.
77. Berek JS, Hacker NF, Lagasse LD. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983; 61: 1989-93.
78. Luesley D, Lawton F, Blackledge G, Kelly K. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 1988; 2: 599-603.
79. Dauplat J, Fernere JP, Gorbinet M. Second-look laparotomy in management epithelial ovarian carcinoma. Cancer 1986; 57: 1627.
80. Lippman SM, Albertts DS, Slymen DJ. Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration. Cancer 1988; 61: 2571-7.
81. Morris M, Gershenson DM, Wharton JT. Secondary ovarian cancer: non responders to first-line therapy. Gynecol Oncol 1989; 33: 1-5.
82. Podratz KC, Schray MF, Wieand HS. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988; 31: 9-24.
83. Hoskins WJ, Rubin SC, Dulaney E. Influence of secondary cytoreduction at the time of second-look laparotomy on survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989; 34: 365-71.
84. Michel G, Zarca D, Castaigne D, Prade M. Secondary cytoreductive surgery in ovarian cancer. Eur J Surg Oncol 1989; 15: 201-4.
85. Rubin SC, Hoskins WJ, Benjamin I. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol 1989; 34: 16-9.
86. Helmkamp BF, Kimmel J. Conservative management of small bowel obstruction. Am J Obstet Gynecol 1985; 152: 677-9.
87. Krebs H-B, Goplerud DR. Surgical management of bowl obstruction in advanced ovarian carcinoma. Obstet Gynecol 1983; 61: 327-30.
88. Bastounis E, Hadjinikolaou L, Ioannou N, Papastmatiou M, Toumbis E, Makri G. Somatostatin as adjuvant therapy in the management of obstructive ileus. Hepatogastroenterology 1989; 36: 538-9.